Pharmaceutical

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.

Individual investors, institutional investors, advisors, and analysts are invited to attend.

REGISTER NOW AT: https://bit.ly/3pKmIit

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations and schedule 1x1 meetings.

NEW CONFERENCE FEATURE: Ability to schedule 1x1 meetings with presenting companies' management.

"We are delighted to highlight industry leaders from the life science sector," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Our Virtual Investor Conferences continue to provide a unique opportunity for these companies to connect with a broader investor base and further communicate their strategies."

March 10 th Agenda:

Eastern
Time (ET)
Presentation Ticker(s)
10:30 AM VolitionRX Limited NYSE American: VNRX
11:00 AM nDatalyze Corp. OTCQB: NDATF | CSE: NDAT
11:30 AM Khiron Life Sciences Corp. OTCQX: KHRNF | TSX-V: KHRN
12:00 PM Universal Ibogaine OTCQB: IBOGF | TSX-V: IBO
12:30 PM Alpha Cognition OTCQB: ACOGF | TSX-V: ACOG
1:00 PM Resverlogix Corp. Pink: RVXCF | TSX: RVX
1:30 PM Satellos Bioscience Inc. Pink: MSCLF | TSX-V: MSCL

To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com .

About Virtual Investor Conferences ®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

IBO:CA
Universal Ibogaine

Universal Ibogaine


Keep reading...Show less
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022 .

Universal Ibogaine Co Founder Dr. Alberto Sola to present at From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine (CNW Group/Universal Ibogaine Inc.)

The Research to Reality event is presented by the Mental Health Commission of Canada , the Center for Addiction and Mental Health ("CAMH") and the Canadian Center on Substance Abuse and Addiction.

The event will be attended by researchers, clinicians' policy makers including representatives from Health Canada the FDA and the Mexico Ministry of Health ("COFEPRIS").

Dr. Sola, is a co-founder of Universal Ibogaine and a member of the Board of Directors, and he is the founder of the Clear Sky Recovery ibogaine clinic operating in Cancun , Mexico.  Alberto is a global leader in ibogaine detox treatments. He will present his latest findings in a panel titled " Ibogaine Hydrochloride and Acute Opioid Detox ., which will take place on Saturday May 28 at 4:15 PM EST "

UI CEO Nick Karos noted: "The importance of this event cannot be overstated.  This is the first event of its kind to bring together academic researchers, real world technicians and government policy makers. We believe this event will be an important catalyst for the industry and a significant milestone for our company.  This event will create awareness at the highest levels of the incredible potential of ibogaine."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.
Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Related Links
https://universalibogaine.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-co-founder-dr-alberto-sola-to-present-at-upcoming-research-to-reality-conference-301547153.html

SOURCE Universal Ibogaine Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/13/c5432.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.

Universal Ibogaine engages Shayne Nyquvest as Capital Markets Advisor (CNW Group/Universal Ibogaine Inc.)

Mr. Nyquvest has extensive capital markets experience, with over 40 years involvement in aiding companies strategic fund-raising activities, in the mining, cannabis and other emerging industries.  He served as the former Executive Vice-President of investment banking firm Mackie Research Capital (where he worked from June 2015 to July 2018 ) and a was founding member of Canaccord Genuity Group, where he worked as a Senior Investment Advisor from 1993 to 2013.

Mr. Nyquvest co-founded UI in early 2018, after personally seeing the transformational effects and potential of ibogaine and was involved in UI's early-stage development until mid-2021.  His vision has been to see this innovative, plant-based treatment adopted by the mainstream medical community as a solution to helping break the opioid epidemic and other addictions.

Nick Karos , UI CEO noted "we are pleased to have Shayne re-engaged in our strategic, business development goals.  He has an extensive network in the investment community and was instrumental in UI's early-stage financing and research activities.  We continue to advance our planned Health Canada clinical trials application for the use of ibogaine in opioid use disorder and expect to provide additional updates on this in the near future."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-retains-shayne-nyquvest-as-capital-markets-advisor-301536451.html

SOURCE Universal Ibogaine Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

(TheNewswire)

Universal Ibogaine Inc.

Calgary, AB TheNewswire - April 21, 2022 Universal Ibogaine Inc. ( TSXV:IBO ) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the UI Board of Directors to pursue other opportunities.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

Universal Ibogaine Inc. (TSXV: IBO) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (" Kelburn ") due to an on-site flooding issue.

Universal Ibogaine Update on Kelburn Operations (CNW Group/Universal Ibogaine Inc.)

Kelburn is UI's addiction treatment site operating near Winnipeg, Manitoba , and which experienced abnormally high winter snowfall conditions, resulting in high current groundwater levels arising from spring melt conditions. Kelburn is currently assessing options for continuation of in-process patient treatment, and remediation of damages, which will fall under Kelburn's property and business interruption insurance coverage, subject to policy limits. The timing for remediation and ultimate re-opening of operations at Kelburn is not determinable, but will likely require a minimum of 2 to 3 months.

Nick Karos (CEO) noted "this is of course an unfortunate unforeseen event, and our first priority is to ensure the continuity of ongoing care of our patient group. The extent of damage will hopefully be contained to a portion of the basement, and allow us to resume on-site operations in a reasonable time frame."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur. The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Related Links

Universal Ibogaine

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-provides-update-on-kelburn-recovery-center-operations-301520593.html

SOURCE Universal Ibogaine Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2022/07/c7462.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

 Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the " FSE ") under the ticker symbol " JC4 ".  UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker symbol IBOGF.

Universal Ibogaine Inc. Logo (CNW Group/Universal Ibogaine Inc.)

The FSE is the largest stock exchange in Germany and is the premiere European destination for Canadian Venture companies looking to build exposure and liquidity with the European market.  The FSE facilitates advanced electronic trading, settlement and information systems allowing it to meet the growing requirements of cross-border trading.

Global Addiction and the Overdose Crisis

According to an August 4, 2021 , World Health Organization report, worldwide approximately 500,000 deaths annually can be attributed to drug use, with more than 70% related to opioids.

" The number of opioid overdoses has increased in recent years in several countries, in part due to the increased use of opioids in the management of chronic pain and increasing use of highly potent opioids appearing on the illicit drug market.

In the United States of America ( USA ) the number of people dying from opioid overdose increased by 120% between 2010 and 2018, and two-thirds of opioid-related overdose deaths in 2018 in the USA involved synthetic opioids, including fentanyl and its analogues.

During the COVID-19 pandemic, a further substantial increase in drug overdose deaths was reported in the USA , primarily driven by rapid increases in overdose deaths involving synthetic opioids. "

https://www.who.int/news-room/fact-sheets/detail/opioid-overdose

What is ibogaine?

Ibogaine is a plant derived neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state and has demonstrated particular effectiveness in treating opioid use disorder in many countries.  When applied according to a strict safety protocol, including a medically supervised setting, ibogaine appears to eliminate the most painful symptoms of opioid withdrawal and can provide a several month window free of drug cravings.  Dr. Alberto Sola , co-founder and member of the Board of Directors of Universal Ibogaine, has administered more ibogaine treatments than any other doctor in the world at an independent clinic (of which he is a partner) in Cancun , Mexico.

The Universal Ibogaine Mission

Universal Ibogaine is a Canadian company which holds the global licensing rights to the ibogaine based addiction treatment protocol developed by Dr. Alberto Sola .  UI is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the ibogaine treatment protocol for opioid use disorder(s).  Upon eventual completion of the trial and Health Canada approval, UI intends to license the protocol to a global network of addiction treatment clinics.  Ibogaine can be very effective for long term addiction cessation when combined with an aftercare treatment program.  Universal Ibogaine operates an addiction treatment facility in Winnipeg , where it is intends to develop best in class addiction treatment programs built around evidence based treatments and nuovo modalities.

Universal Ibogaine CEO Nick Karos commented "the FSE listing is a key piece of our capital markets and investor relations strategy.  We have recently commenced trading on the OTCQB Exchange in the USA , and interest in the UI story is growing in Europe and Germany in particular. Germany has a history of innovation and leadership with an emerging market and interest in psychedelic medicines."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Related Links

https://universalibogaine.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-announces-frankfurt-stock-exchange-listing-301518668.html

SOURCE Universal Ibogaine Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
CSE Bulletin: Consolidation - Silo Wellness Inc.

CSE Bulletin: Consolidation - Silo Wellness Inc.

Silo Wellness Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty (20) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 4,268,237 common shares.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be considering participation in the regulatory regime under Oregon Ballot Measure 109. "With Silo Wellness as the only publicly traded psychedelic company with legal psychedelic retreat experience and a strong connection to Oregon, we believe we are well positioned to collaborate with other Oregonians interested in participating in this burgeoning market," stated Silo Wellness founder and Oregon lawyer Mike Arnold.

"Over the past months we have been touring properties with owners and realtors and have really turned up our search for properties that may be suitable for Oregon psilocybin as we await the final rules from the Oregon Health Authority," Mr. Arnold continued. "However, I also know that there are many property owners who may believe they are sitting on an ideal property for a facility with no interest in selling, but they may not have the legal expertise, network, or capital to make it happen. It is our goal to leverage our platform to help empower Oregonians who may each have a piece of the puzzle - facilitation experience, business experience, property, capital, or a passion for the medicine - and bring them together to help make this industry by Oregonians for Oregonians."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, announced today that Silo Wellness founder and chairman of the board of directors Mike Arnold is assuming the role of the Company's interim chief executive officer to continue to lead the Company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The Company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. The Board would like to thank him for his leadership over the past two years.

CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney (complex criminal defense and commercial litigation). As the Company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12M for his startups.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into an exploratory supply agreement with ATMA Journey Centers ("ATMA"), a privately held facilitator of psilocybin-assisted therapy and practitioner training services for palliative care and mental health conditions based in Calgary, Alberta.

The Company has finalized an agreement which will supply psilocybin products to ATMA for future therapist initiatives and supply requirements.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Filament Health ("Filament") (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company.

Optimi has been engaged by Filament to supply psilocybin mushrooms cultivated in Optimi's recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia facility in the form of whole, dried mushroom fruiting bodies for potential drug development, testing, and analysis by Filament's research team.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Silo Wellness to Create a Psychedelic Pharmaceutical Manufacturing and Research Portfolio with Proposed Acquisition of Dyscovry Science

Silo Wellness to Create a Psychedelic Pharmaceutical Manufacturing and Research Portfolio with Proposed Acquisition of Dyscovry Science

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that it has executed a nonbinding letter of intent to acquire 100% of Dyscovry Science Ltd., a Toronto-based biotechnology company. Dyscovry focuses on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome. With Dyscovry's research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psilocybin and its potentially novel molecule derivatives.

"We have been working with Brad Dottin and his team at Dyscovry for almost a year now planning this transaction," commented Mike Arnold, Silo Wellness's president and founder. "We have watched the psychedelic market get pummeled as many have been chasing the 'me too' pharma deals, while we stayed focused on preparing for Oregon adult use with a successful Jamaican retreat model while, in the background, working on this unique opportunity. For the first time under one roof, a publicly traded company will provide psychedelic healing right now through Jamaican psychedelic wellness retreats while at the same time innovating the 'what's next' for psychedelic pharmaceutical healing. As an Oregon attorney who founded Silo Wellness in 2018 with the goal of preparing for psilocybin legalization in Oregon, I wanted to ensure that natural psychedelics were never locked up solely behind a pharmacy window controlled by corporations. Our planned acquisition of Dyscovry shows that traditional medicines can coexist alongside modern scientific innovation."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×